Loading…
Loading…
CBSC does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CBSC and 80,000+ other tickers.
See exactly how CBSC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CBSC and 80,000+ other tickers.
Operating globally through its international subsidiaries, Cardiac Biotech Solutions Inc. delivers advanced products and services for non-invasive, mobile cardiac monitoring. The company's portfolio includes FDA and CE-approved EKG devices, sophisticated cloud-based data acquisition software, and intuitive smartphone applications compatible with both iOS and Android platforms. These solutions are designed to boost patient engagement for individuals prone to irregular heart rhythms, simultaneously providing medical professionals with highly accurate diagnostic insights. Furthermore, its wholly…
Cardiac Biotech Solutions (OTCMKTS:CBSC - Get Free Report) and ADMA Biologics (NASDAQ: ADMA - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk. Institutional and Insider Ownership 75.7% of ADMA
LAS VEGAS, Sept. 25, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Cardiac Biotech Solutions, Inc.
LAS VEGAS, Sept. 11, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Cardiac Biotech Solutions, Inc.
LAS VEGAS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the execution of a new distribution agreement with Noventis Medical, granting the Company five-year exclusive rights to distribute CBSC's products across Costa Rica, Panama, Colombia, and Argentina.
LAS VEGAS, NV / ACCESS Newswire / May 8, 2025 / Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, announced today that the Company's name was changed to "Cardiac Biotech Solutions, Inc." effective May 7, 2025, following completion of the review of the Company's application to change its name by the Financial Industry Regulatory Authority (FINRA) and approval of the name change at the annual meeting of the Company's shareholders held on March 14, 2024. The name change will not impact the Company's current CBSC ticker symbol, nor will it affect the Company's assigned CUSIP number, the unique nine-digit identification number assigned to financial securities in the United States and Canada.